Characterization of cell states in biliary tract cancers identifies mechanisms of therapeutic resistance in a phase II trial of DKN-01/nivolumab
Ryan J. Park(Broad Institute), Lipika Goyal(Massachusetts General Hospital)
Cited by 2
Related Papers
Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
|Cancer Discovery|2016|539
FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures
|Clinical Cancer Research|2022|14